电子文档交易市场
安卓APP | ios版本
电子文档交易市场
安卓APP | ios版本

乳腺癌辅助治疗规范的解读(肿瘤医院内科)

93页
  • 卖家[上传人]:jct2****808
  • 文档编号:111661252
  • 上传时间:2019-11-03
  • 文档格式:PPT
  • 文档大小:8.42MB
  • / 93 举报 版权申诉 马上下载
  • 文本预览
  • 下载提示
  • 常见问题
    • 1、1,乳腺癌辅助治疗规范的解读,肿瘤医院内科,2,Treatment Guidelines are useful,Guidelines provide a benchmark and integrate new findings into clinical practice They are dynamic documents, which need periodic update They are developed to reduce under-treatment, over-treatment and wrong treatment Compliance with guidelines has been shown to improve patient outcome,3,Adjuvant Therapy for Breast Cancer Treatment Guidelines,78,83,88,92,95,98,01,03,05,80,85,90,2000,Guidelines,St. Gallen,NIH,NCCN,96,yearly,07,如何掌握、使用?,4,讨论内容

      2、,辅助治疗对哪些人有益? 如何选择哪种辅助治疗方法? 化疗方案的选择 分子靶向治疗作用 内分泌治疗方法的选择,5,Adapted from Bonadonna G. Cancer Res. 1992.,All Patients,1 3 5 7 9 11 13 15 years,LOG-RANK : P = 0.002 WILCOXON : P = 0.0001,100 50 0,% Relapse-free survival,CMF Surgery,36% 26%,1 3 5 7 9 11 13 15 years,LOG-RANK : P = 0.02 WILCOXON : P = 0.02,100 50 0,% Overall survival,CMF Surgery,51% 35%,Breast Cancer: Adjuvant CMF (12 months) or Surgery Alone,Premenopausal,6,30 years follow up of randomised studies of adjuvant CMF in Operable breast can

      3、cer : cohort study,Relapse free survival,Overall survival,Bonadonna BMJ 330:217, 2005,复发相对危险降低 34% HR 0.71 ( P = 0.005 ),各种死亡降低 22% HR 0.79 ( P = 0.04 ),7,30 years follow up of randomised studies of adjuvant CMF in Operable breast cancer : cohort study,Overall survival,Bonadonna BMJ 330:217, 2005,8,Comparative Efficacy of Adjuvant Chemotherapy: EBCTCG Meta-Analyses,Therapy,Reduction in Annual Odds, %,Recurrence,Death,Polychemotherapy vs 23.5 15 no chemotherapy (1995) (P .00001) (P .00001) Anthra

      4、cyclines vs 12 11 CMF (1995) (P = .006) (P = .02) Anthracyclines vs 10.8 15.7 CMF (2000) (P = .0005) (P .00001),9,2000 Oxford Overview Analysis A/E+ vs CMF: All Deaths,0.5,1.5,2.0,15.7% (SE 3.) reduction 2p 0.00001,Deaths/Women Allocated Adjusted A/E+ CMF*,A/E+ Deaths Logrank Variance OE of OE,Year Code and Study Name,Months & Treatment,76A4 SECSG 2,6FAC v 6CMF,93/260,89/268,-2.9,41.6,78L2 ONCOFRANCE,12FACV v 12CMF,52/138,58/113,-10.9,25.0,80C1 SE Sweden BCG A,8AC v 7CMF (+R),8/21,13/22,-2.2,5.0

      5、,80M INT Milan,8CMF+4A v 12CMF,-/211,-/212,(no data),83A NSABC Israel Br0283,2CMF+4AVbCMF v 6CMF,23/55,21/50,-1.3,10.1,84B NSABP B-15*,4AC3CMF v 6CMF (+R),716/1562,2(374/776),-14.8,224.7,84K1 GUN-3 Naples,3CMFEV v 6CMF,45/105,58/115,-5.2,23.7,84L ICCG Charing Cross,8/6FEC v 6CMF,20/256,32/259,-5.5,11.8,84Q2 Austrian BCSG 3,6CMFVA v 6CMF,67/121,75/124,-3.1,30.8,85Y1 PRONACAM85 N+/Pre,FECM v CMF,(no data),86G2 NHG Japan,10FAC c 10CMF ( Tam),(no data),87D4+5+6 GABG 3 Germany,6FEC v 6CMF ( Tam),52/1

      6、42,60/146,-7.5,23.6,87Q1 PRONACAM 87,4/5CMFEP v 6CMF,(no data),88R Brussels Belgium*,8EC v 6CMF,138/537,2(69/267),2.1,44.1,88V H San Carlos, Madrid,6FAC v 6CMF,(no data),89B2 SWOG 8897,6FAC v 6CMF (+RTam),173/1461,223/1470,-25.9,97.1,89R NCI-C MA.5,6FEC v 6CMF,118/356,135/360,-10.1,59.1,89W123456c Denmark-Sweden*,9FEC V9CMF (+Pmd),150/601,0.8(290/781),-31.8,91.0,91H NSABP B-23 ER-,AC v CMF (+Tam),91/1003,100/1005,-5.5,46.8,91Q GUN MAM1 Naples,ZolTaM+(A;CMF v CMF),34/232,43/234,-3.8,18.2,94J1+2+3

      7、 GOIRC SANG 2B Italy,6CMFEV v 6CMF (+Tam),(no data),Scottish,4E;4CMF v 8CMF,(no data),1780/ 6850 (26.0%),-128.4,2019/ 6906 (29.2%),752.5,Total *,99% or 95% CI,A/E+ better,CMF better,Treatment effect 2p 0.00001, 1 trial with no data does not contribute to total (allocated A/E+: 211; allocated CMF: 212) * For balance, control patients in 3-way trial strata count half or twice in subtotal(s) and in final total of events/women.,1.0,0,(? Patients),(100 Patients),(322 Patients),(158 Patients),( 480 Pa

      8、tients),(? Patients),Ratio of annual death rates A/E+ : CMF,10,11,12,HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344,D.F.Hayes ASCO 2006 Abs510,ER+,13,BCIRG 001 Study Design,Docetaxel 75 mg/m2 Doxorubicin 50 mg/m2 Cyclophosphamide 500 mg/m2,5-FU 500 mg/m2 Doxorubicin 50 mg/m2 Cyclophosphamide 500 mg/m2,R,Dexamethasone premedication, 8 mg bid, 3 days Prophylactic Cipro 500 mg bid, day 5-14,Every 3 weeks x 6 cycles,Stratification: Nodes: 1-3 4+ Ce

      9、nter,14,TAC,FAC,0,6,12,18,24,30,36,42,48,Months,Number at Risk,TAC,FAC,745,736,710,678,654,373,152,23,1,746,729,699,656,605,334,150,31,0,50,60,70,80,90,100,% Alive and Disease Free,Disease Free Survival (ITT),BCIRG 001,Median follow-up: 33 months,15,Number at Risk,TAC,FAC,745,741,732,718,700,393,171,24,1,746,738,728,713,678,375,171,33,1,Overall Survival (ITT),BCIRG 001,TAC,FAC,0,6,12,18,24,30,36,42,48,Months,50,60,70,80,90,100,% Alive,Median follow-up: 33 months,16,Disease Free Survival by Hormonal Status,TAC,FAC,0,12,24,36,48,Months,N at Risk,TAC,FAC,231,217,188,47,0,228,202,158,34,0,50,60,70,80,90,100,% Alive and Disease Free,TAC,FAC,0,12,24,36,48,Months,N at Risk,TAC,FAC,514,493,466,105,1,518,497,447,116,0,50,60,70,80,90,100,Negative,Positive,RR = 0.62 p = 0.005

      《乳腺癌辅助治疗规范的解读(肿瘤医院内科)》由会员jct2****808分享,可在线阅读,更多相关《乳腺癌辅助治疗规范的解读(肿瘤医院内科)》请在金锄头文库上搜索。

      点击阅读更多内容
    最新标签
    发车时刻表 长途客运 入党志愿书填写模板精品 庆祝建党101周年多体裁诗歌朗诵素材汇编10篇唯一微庆祝 智能家居系统本科论文 心得感悟 雁楠中学 20230513224122 2022 公安主题党日 部编版四年级第三单元综合性学习课件 机关事务中心2022年全面依法治区工作总结及来年工作安排 入党积极分子自我推荐 世界水日ppt 关于构建更高水平的全民健身公共服务体系的意见 空气单元分析 哈里德课件 2022年乡村振兴驻村工作计划 空气教材分析 五年级下册科学教材分析 退役军人事务局季度工作总结 集装箱房合同 2021年财务报表 2022年继续教育公需课 2022年公需课 2022年日历每月一张 名词性从句在写作中的应用 局域网技术与局域网组建 施工网格 薪资体系 运维实施方案 硫酸安全技术 柔韧训练 既有居住建筑节能改造技术规程 建筑工地疫情防控 大型工程技术风险 磷酸二氢钾 2022年小学三年级语文下册教学总结例文 少儿美术-小花 2022年环保倡议书模板六篇 2022年监理辞职报告精选 2022年畅想未来记叙文精品 企业信息化建设与管理课程实验指导书范本 草房子读后感-第1篇 小数乘整数教学PPT课件人教版五年级数学上册 2022年教师个人工作计划范本-工作计划 国学小名士经典诵读电视大赛观后感诵读经典传承美德 医疗质量管理制度 2 2022年小学体育教师学期工作总结 2022年家长会心得体会集合15篇
     
    收藏店铺
    关于金锄头网 - 版权申诉 - 免责声明 - 诚邀英才 - 联系我们
    手机版 | 川公网安备 51140202000112号 | 经营许可证(蜀ICP备13022795号)
    ©2008-2016 by Sichuan Goldhoe Inc. All Rights Reserved.